GRAL ▲ +1.3% - GRAIL, Inc. $GRAL GRAL - FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test GRAIL shares rose 1.3% following a positive recommendation from an FDA Advisory Committee in favor of approving the company's Galleri multi-cancer early detection blood test. The favorable vote represents a significant regulatory milestone for the test, which aims to detect multiple cancer types in asymptomatic individuals. 23-SEP-2026 06:18 PM ET